Organigram Global (NASDAQ: OGI) has affirmed that its revenue for fiscal year 2026 is expected to exceed $255.197 million, surpassing the previous market estimate of $241.360 million. This upward revision indicates stronger-than-anticipated performance and suggests robust demand dynamics within the cannabis sector for the full year. The company’s ability to project revenue well above consensus estimates reflects confidence in its operational execution and market positioning during the period.

The guidance update serves as a key indicator of the company’s financial trajectory, with the revised figure representing a notable premium over analyst expectations. By confirming revenue levels above the $241.360 million benchmark, Organigram Global signals effective management of its business operations amidst prevailing market conditions. The affirmation underscores the company’s focus on delivering value to shareholders through improved top-line performance.

Financial Guidance Update

The following table outlines the revised revenue expectations compared to the prior estimates:

What the Numbers Show

The gap between the affirmed revenue expectation of $255.197 million and the estimated $241.360 million represents a significant positive variance. This divergence suggests that underlying sales volumes or pricing power may have strengthened beyond initial forecasts. For investors, this revision provides a clearer picture of the company’s near-term financial health and its capacity to capitalize on current market opportunities in the cannabis industry.

Organigram Global Inc. has maintained its position as Canada's leading cannabis company by market share, reporting strong performance in its core categories and confirming that its recently acquired Sanity Group GmbH is meeting revenue expectations. The company provided a business update highlighting initial operating performance from Sanity, continued strength in its Canadian business, and upcoming investor engagement ahead of its Q3 Fiscal 2026 earnings release.

"The first quarter following the acquisition of Sanity marks an important milestone for Organigram as we will begin reporting the financial contribution from our international business," said James Yamanaka, Chief Executive Officer. "Sanity's initial performance has been consistent with our expectations at the time of acquisition, while our Canadian business continues to demonstrate resilience through market leadership."

Sanity Group Performance

Since the closing of the acquisition on April 15, 2026, Sanity has maintained an average market share of approximately 10% in Germany and has performed in line with the revenue expectations established at the time of acquisition. The company noted that recently announced regulatory changes in Germany regarding reimbursement eligibility for medical cannabis are not expected to have a material impact on Sanity's business, as reimbursement-based sales represent approximately 1% of total revenue.

Canadian Market Share

Organigram continues to hold leading positions across Canada's largest cannabis categories. The company reported the following market share figures:

Together, these categories represent more than 86% of total Canadian recreational cannabis retail sales. The company also recorded significant year-over-year market share gains in beverages, increasing by 3.1 percentage points, and concentrates, rising by 3.3 percentage points.

Operational Performance

During June, Organigram stabilized vape market share declines experienced earlier in Q2 Fiscal 2026, with all-in-one vape share improving approximately 1 percentage point compared to the previous month. Distribution of the company's new all-in-one vape portfolio has expanded to every Canadian province except Nova Scotia and Quebec. Similarly, both pre-roll and infused pre-roll market share improved sequentially during June, reflecting operational improvements implemented during Q2 Fiscal 2026.

At the end of June, Organigram held an 11.1% share of the Canadian recreational cannabis market, down 0.4 percentage points year-over-year. Sequentially, the company’s market share improved 100 basis points versus May. The company continues optimizing its SKU count to focus resources on delivering higher SKU-level performance and operational efficiencies.

Upcoming Reporting

Organigram expects to report its Q3 Fiscal 2026 financial results on or about August 11, 2026. This will represent the first quarter to include consolidated financial results from both Organigram and Sanity. The company also plans to host its second Digital Investor Session in late September 2026 to discuss its longer-term strategy.